Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase.
A high-performance liquid chromatographic assay has been developed and validated for the determination of the anticancer agent CI-980 in plasma samples from pediatric patients. After ether extraction from alkaline plasma, the CI-980 was chromatographed on a (R)-N-(3,5-dinitrobenzoyl)phenylglycine stationary phase using a mobile phase composed of hexane-isopropanol (70:30, v/v) modified with 1% acetonitrile. The method was linear over a 0.25 to 25.00 ng/ml range and the intra- and inter-day coefficients of variation (C.V.s) were less than 15%. The method was applied to the determination of the plasma concentration-time profile for a pediatric patient receiving 3.5 mg/m2 of CI-980 per day as a continuous 72-h infusion.
Markoglou
N
N
McGill University, Department of Oncology, Montreal, Quebec, Canada.
Wainer
I W
IW
D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002219:Carbamates / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002853:Chromatography, Liquid; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D011719:Pyrazines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D002219:Carbamates; D011719:Pyrazines; D011725:Pyridines; C072383:canertinib dihydrochloride